Ulipristal Acetate for Use in Early Pregnancy Loss
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The investigators will study the feasibility of using 90mg ulipristal acetate, a selective
progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical
management of early pregnancy loss. Patients will be followed to assess effective treatment
of early pregnancy loss, additional interventions needed, side effects, adverse events and
patient acceptability.